Neximmune Stock Retained Earnings
NEXIDelisted Stock | USD 2.43 0.22 9.95% |
Neximmune fundamentals help investors to digest information that contributes to Neximmune's financial success or failures. It also enables traders to predict the movement of Neximmune Pink Sheet. The fundamental analysis module provides a way to measure Neximmune's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Neximmune pink sheet.
Neximmune |
Neximmune Company Retained Earnings Analysis
Neximmune's Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.
More About Retained Earnings | All Equity Analysis
Retained Earnings | = | Beginning RE + Income | - | Dividends |
Current Neximmune Retained Earnings | (222.59 M) |
Most of Neximmune's fundamental indicators, such as Retained Earnings, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Neximmune is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Retained Earnings shows how the firm utilizes its profits over time. In simple terms, investors can think of retained earnings as the amount of profit the company has reinvested in the business since its inceptions. However the methodology to make a decision over how much profit to retain is different between companies in different industries. For example, growing industries tend to retain more of their earnings than more matured industries as they need more assets investment to sustain their growth.
CompetitionBased on the latest financial disclosure, Neximmune has a Retained Earnings of (222.59 Million). This is 123.9% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The retained earnings for all United States stocks is 102.39% higher than that of the company.
Neximmune Retained Earnings Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Neximmune's direct or indirect competition against its Retained Earnings to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Neximmune could also be used in its relative valuation, which is a method of valuing Neximmune by comparing valuation metrics of similar companies.Neximmune is currently under evaluation in retained earnings category among its peers.
Neximmune Fundamentals
Return On Equity | -1.96 | ||||
Return On Asset | -0.7 | ||||
Current Valuation | (491.95 K) | ||||
Shares Outstanding | 1.37 M | ||||
Shares Owned By Insiders | 17.00 % | ||||
Shares Owned By Institutions | 11.17 % | ||||
Number Of Shares Shorted | 15.99 K | ||||
Price To Book | 1.38 X | ||||
EBITDA | (28.17 M) | ||||
Net Income | (32.34 M) | ||||
Cash And Equivalents | 53.13 M | ||||
Cash Per Share | 2.20 X | ||||
Total Debt | 68.81 K | ||||
Debt To Equity | 0.02 % | ||||
Current Ratio | 6.54 X | ||||
Book Value Per Share | 2.00 X | ||||
Cash Flow From Operations | (31.43 M) | ||||
Short Ratio | 2.26 X | ||||
Earnings Per Share | (24.11) X | ||||
Target Price | 2.0 | ||||
Beta | 1.94 | ||||
Market Capitalization | 3.25 M | ||||
Total Asset | 8.59 M | ||||
Retained Earnings | (222.59 M) | ||||
Working Capital | 316.73 K | ||||
Net Asset | 8.59 M |
About Neximmune Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Neximmune's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Neximmune using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Neximmune based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Other Consideration for investing in Neximmune Pink Sheet
If you are still planning to invest in Neximmune check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Neximmune's history and understand the potential risks before investing.
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |